August 4, 2011

The world's top-selling drug may become available over the counter, if its manufacturer has its way, according to published reports.

August 3, 2011

Par Pharmaceutical had sales of $224.2 million and profits of $9.05 million during second quarter 2011, the drug maker said Wednesday.

August 2, 2011

The Food and Drug Administration has approved a new use for a drug made by Novartis for treating multiple sclerosis, the Swiss drug maker's U.S. subsidiary said Monday.

August 2, 2011

The Food and Drug Administration has granted orphan drug designation to a chemotherapy drug made by Merrimack Pharmaceuticals for pancreatic cancer, the drug maker said Monday.

August 1, 2011

A federal court has upheld Eli Lilly's patent covering a drug used to treat attention deficit hyperactivity disorder, Lilly said Friday.

August 1, 2011

The Food and Drug Administration has approved a generic version of a short-term adjunct treatment for obesity.

August 1, 2011

In a report issued last week, the National Association of Boards of Pharmacy found that 96% of rogue websites analyzed continue to operate out of compliance with U.S. pharmacy laws, fuel prescription drug abuse and misuse, and provide an outlet for counterfeit medicines to enter the U.S. drug supply.

July 29, 2011

A generic version of a popular pneumonia treatment has entered the market from Hi-Tech Pharmacal.

July 29, 2011

The Food and Drug Administration has approved a generic drug for diabetes made by Indian generic drug maker Strides Arcolab.

July 29, 2011

Teva Pharmaceuticals has launched an authorized generic version of a contraceptive made by Duramed Pharmaceuticals, Teva said.

July 28, 2011

Biogen Idec has expanded its online resource for patients living with multiple sclerosis to include new resources and support programs.

July 28, 2011

Drug makers Eli Lilly, Amylin Pharmaceuticals and Alkermes are giving their long-acting form of an injected drug for Type 2 diabetes another try at the Food and Drug Administration.

July 28, 2011

GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

July 28, 2011

Pfizer has entered a definitive agreement to acquire a biopharmaceutical company that focuses on the development of pain treatments.

July 28, 2011

The president and CEO of Sanofi's U.S. operations is stepping into a newly created role at the drug maker.

July 28, 2011

Generic drug maker Watson Pharmaceuticals has launched a generic version of a contraceptive made by Duramed Pharmaceuticals, Watson said Thursday.

July 27, 2011

Eli Lilly has launched its physician payment registry, a website that enables visitors to search payments to individual U.S.-based physicians and the institutions or research organizations that receive payments on behalf of a physician.

July 26, 2011

Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.

July 26, 2011

Watson Pharmaceuticals had sales of $1.1 billion during second quarter 2011, the generic drug maker said.

July 25, 2011

Health care is like precision engineering; tweaking one element ever so slightly can mean the difference between a healthy life and an early death or, in the case of drug spending, between nearly $50,000 and just north of $1,000.


July 25, 2011


The Food and Drug Administration last month published long-awaited draft guidance on new dietary ingredients in the Federal Register.

July 25, 2011

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said.

July 21, 2011

The Food and Drug Administration has approved a drug made by AstraZeneca to reduce the rate of heart attacks in patients with acute coronary syndrome, the Anglo-Swedish drug maker said.

July 20, 2011

A Food and Drug Administration committee of experts has advised against approving a drug for Type 2 diabetes made by AstraZeneca and Bristol-Myers Squibb, the companies said Tuesday.